<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00142818</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-12756-3</org_study_id>
    <secondary_id>P50DA012756-03</secondary_id>
    <secondary_id>DPMC</secondary_id>
    <nct_id>NCT00142818</nct_id>
  </id_info>
  <brief_title>Modafinil and Naltrexone to Reduce Cocaine and Alcohol Dependence</brief_title>
  <acronym>Mod-Nal</acronym>
  <official_title>A Phase II, Double-blind, Placebo-Controlled, Pilot Trial of the Combination of Modafinil and Naltrexone for the Treatment of Cocaine and Alcohol Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyle Kampman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Modafinil is a medication that may enhance mood and increase energy in cocaine addicts, which
      may be useful in preventing cocaine relapse. Naltrexone is a medication that is currently
      used to treat drug and alcohol addiction. A combination of these two medications may be
      beneficial in reducing drug and alcohol use in individuals undergoing substance abuse
      treatment. The purpose of this study is to evaluate the effectiveness of modafinil and
      naltrexone, alone and in combination, at reducing drug and alcohol use in individuals
      addicted to cocaine and alcohol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cocaine and alcohol addiction are serious health problems with no available medical treatment
      for preventing relapse. Past research has shown that individuals who are addicted to both
      cocaine and alcohol typically respond poorly to conventional substance abuse treatment.
      Little attention has been directed towards how best to treat these individuals. Naltrexone is
      a medication that is currently used to treat drug and alcohol addiction. It acts by blocking
      the &quot;high&quot; feeling produced by drugs and alcohol. Modafinil, another medication, enhances
      mood, increases energy, and improves concentration in people with narcolepsy. Preliminary
      research has shown that it may produce similar effects to cocaine, thereby potentially
      countering the symptoms of cocaine withdrawal. Cognitive Behavioral Coping Skills Therapy
      (CBT), a form of therapy that aims to alter an individual's patterns of behavior and drug
      use, is also an important component of substance abuse treatment. The purpose of this study
      is to compare the effectiveness of CBT plus placebo, CBT plus modafinil, CBT plus naltrexone,
      and CBT plus a combination of modafinil and naltrexone at reducing cocaine and alcohol use in
      individuals addicted to both substances.

      This 14-week study will enroll individuals addicted to both cocaine and alcohol. During a
      1-week screening period, potential participants will be required to complete a detoxification
      program, including stopping all cocaine and alcohol use. Participants will also undergo a
      physical exam and an electrocardiogram. Blood will be drawn for laboratory tests, and urine
      tests will be used to screen for the presence of drugs and alcohol. Individuals who complete
      the screening and meet all study requirements will be permitted to participate in the
      treatment phase of the study. During the 13-week treatment phase, participants will be
      randomly assigned to receive modafinil, naltrexone, a combination of modafinil and
      naltrexone, or placebo. All participants will attend a CBT session once a week. Study visits
      will take place twice a week. At each visit, a urine test and breathalyzer will be used to
      screen for the presence of alcohol and drugs. Participants will also complete standardized
      psychological questionnaires to measure drug and alcohol craving, treatment services
      received, severity of illness, and withdrawal symptoms. In addition, participants will meet
      weekly with a nurse practitioner, who will dispense study medications, monitor adverse
      events, and evaluate the participant's clinical status. A follow-up evaluation will occur 6
      months following the end of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cocaine Use (Measured by Timeline Follow Back and Urine Screen at Week 14)</measure>
    <time_frame>13 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Days of Abstinence From Drinking and Number of Days of Clinically Significant Drinking (Measured by Timeline Follow Back at Week 14 and the 6-month Evaluation)</measure>
    <time_frame>4+13 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Naltrexone-treated Subjects Will Demonstrate a Significantly Greater Reduction in Cocaine Use Measured by the Number of BE-negative Urine Samples and Significantly Reduced Alcohol Use Measured by Fewer Days of Clinically Significant Drinking.</measure>
    <time_frame>4+13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modafinil-treated Subjects Will Demonstrate a Significantly Greater Reduction in Cocaine Use Measured by the Number of BE-negative Urine Samples and Significantly Reduced Alcohol Use Measured by Fewer Days of Clinically Significant Drinking.</measure>
    <time_frame>4+13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Naltrexone/Modafinil-treated Subjects Will Have Fewer Days of Cocaine Use, More Abstinent Days From Alcohol, and Fewer Heavy Drinking Days During the Follow up Period Compared to Placebo-treated Subjects.</measure>
    <time_frame>4+13 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">164</enrollment>
  <condition>Alcohol-Related Disorders</condition>
  <condition>Alcoholism</condition>
  <condition>Cocaine-Related Disorders</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nal + Mod</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mod</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone</intervention_name>
    <description>150 mg daily for males; 100 mg daily for females</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>ReVia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Modafinil</intervention_name>
    <description>400 mg daily</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>Provigil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>400 mg and/or 100-150 mg placebo pills</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        4.1 Inclusion Criteria

          1. Male and females, 18 years of age or older.

          2. Meets DSM-IV criteria for current diagnoses of cocaine and alcohol dependence,
             determined by the SCID-IV.

          3. In the past 30 days, used no less than $200-worth of cocaine and meets the following
             drinking criteria as measured by the Timeline Followback (TLFB) (Sobell, 1995):

               1. drank within 30 days of intake day,

               2. reports a minimum of 48 standard alcoholic (avg. 12 drinks/wk) in a consecutive
                  30-day period over the 90-day period prior to starting intake (i.e., a minimum of
                  40% days drinking), and

               3. has 2 or more days of heavy drinking (defined as 5 or more drinks per day in
                  males and 4 or more drinks per day in females) in this same pre-treatment period.

          4. 72 consecutive hours of abstinence from alcohol, determined by self-reports and
             confirmed by a negative breathalyzer tests, and a Clinical Institute Withdrawal Scale
             for Alcohol (CIWA-AR) (Sullivan, 1989) score below eight. Subjects will be encouraged
             to achieve 72 consecutive hours of abstinence, however, subjects who have achieved
             between 48 and 72 consecutive hours of abstinence will be included with the approval
             of the principal investigator. We anticipate that these subjects will comprise less
             than 5% of total enrolled subjects. Subjects will be given 2 additional weeks beyond
             the screening week to attain the appropriate period of alcohol abstinence prior to
             randomization.

          5. Lives a commutable distance from the TRC and agrees to attend all research visits
             including follow-up visits.

          6. Speaks, understands, and prints in English

          7. Ability to give informed consent

        Exclusion Criteria

          1. Abstinent from cocaine or alcohol for 30 consecutive days prior to signing consent
             form.

          2. Meets DSM IV criteria for dependence on any substance other than cocaine and alcohol
             (except nicotine), determined by the SCID.

          3. Needs treatment with any psychoactive medications including any anti-seizure
             medications (with the exception of diphenhydramine used sparingly, if necessary, for
             sleep).

          4. Meets current or lifetime DSM-IV criteria for schizophrenia or any psychotic disorder
             or organic mental disorder. Subject meets current DSM-IV diagnosis of any other
             clinically significant psychiatric disorder that will interfere with study
             participation.

          5. Has evidence of a history of significant hematological, pulmonary, endocrine,
             cardiovascular, renal or gastrointestinal disease (including a history of myocardial
             infarction, mitral valve prolapse, left ventricular hypertrophy, uncontrolled
             hypertension).

          6. Severe physical or medical illnesses such as AIDS, active hepatitis, significant
             hepatocellular injury as evidenced by elevated total bilirubin levels (&gt;1.3 mg/dl),or
             elevated levels (over 4.5x normal) of aspartate aminotransferase (AST), and serum
             glutamic-pyruvic transaminase (SGPT) after the required 3 days of abstinence.

          7. Use of an investigational medication in the 30 days prior to randomization.

          8. History of hypersensitivity to modafinil or naltrexone

          9. Receiving chronic therapy with any drug known to interact adversely with either
             modafinil or naltrexone including propranolol, phenytoin, warfarin, diazepam

         10. Took a monoamine oxidase inhibitor within 30 days of randomization.

         11. Is female and tests positive on a pregnancy test, is contemplating pregnancy in the
             next 6 months, is nursing, or is not using an effective contraceptive method (if
             relevant). Acceptable methods of contraception include barrier methods (diaphragm or
             condom with spermicide, female condom), intrauterine progesterone contraceptive
             system, levonorgrestrel implant, and medroxyprogeterone acetate contraceptive
             injection, copper IUD, vaginal contraceptive film, cervical cap, contraceptive foam.

         12. Current use of an oral contraceptive without other acceptable barrier method of
             contraception.

         13. Received therapy with any opiate substitute (methadone, LAAM, buprenorphine) within 60
             days of randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyle M. Kampman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104 6178</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2005</study_first_submitted>
  <study_first_submitted_qc>September 1, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2005</study_first_posted>
  <results_first_submitted>August 12, 2014</results_first_submitted>
  <results_first_submitted_qc>August 27, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 29, 2014</results_first_posted>
  <last_update_submitted>February 7, 2018</last_update_submitted>
  <last_update_submitted_qc>February 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Kyle Kampman</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Alcohol Abuse</keyword>
  <keyword>Cocaine Abuse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Cocaine-Related Disorders</mesh_term>
    <mesh_term>Alcohol-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Cocaine</mesh_term>
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Modafinil</mesh_term>
    <mesh_term>Armodafinil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ModNal</title>
          <description>Nal + Mod
Naltrexone: 150 mg daily for males; 100 mg daily for females
Modafinil: 400 mg daily</description>
        </group>
        <group group_id="P2">
          <title>Naltrexone and Placebo</title>
          <description>Nal
Naltrexone: 150 mg daily for males; 100 mg daily for females</description>
        </group>
        <group group_id="P3">
          <title>Modafinil and Placebo</title>
          <description>Mod
Modafinil: 400 mg daily</description>
        </group>
        <group group_id="P4">
          <title>Double Placebo</title>
          <description>Placebo
Placebo: 400 mg and/or 100-150 mg placebo pills</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="37"/>
                <participants group_id="P4" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ModNal</title>
          <description>Nal + Mod
Naltrexone: 150 mg daily for males; 100 mg daily for females
Modafinil: 400 mg daily</description>
        </group>
        <group group_id="B2">
          <title>Naltrexone and Placebo</title>
          <description>Nal
Naltrexone: 150 mg daily for males; 100 mg daily for females</description>
        </group>
        <group group_id="B3">
          <title>Modafinil and Placebo</title>
          <description>Mod
Modafinil: 400 mg daily</description>
        </group>
        <group group_id="B4">
          <title>Double Placebo</title>
          <description>Placebo
Placebo: 400 mg and/or 100-150 mg placebo pills</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="37"/>
            <count group_id="B4" value="42"/>
            <count group_id="B5" value="164"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="164"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cocaine Use (Measured by Timeline Follow Back and Urine Screen at Week 14)</title>
        <time_frame>13 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ModNal</title>
            <description>Nal + Mod
Naltrexone: 150 mg daily for males; 100 mg daily for females
Modafinil: 400 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone and Placebo</title>
            <description>Nal
Naltrexone: 150 mg daily for males; 100 mg daily for females</description>
          </group>
          <group group_id="O3">
            <title>Modafinil and Placebo</title>
            <description>Mod
Modafinil: 400 mg daily</description>
          </group>
          <group group_id="O4">
            <title>Double Placebo</title>
            <description>Placebo
Placebo: 400 mg and/or 100-150 mg placebo pills</description>
          </group>
        </group_list>
        <measure>
          <title>Cocaine Use (Measured by Timeline Follow Back and Urine Screen at Week 14)</title>
          <units>number of cocaine negative urine samples</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" spread="8.4"/>
                    <measurement group_id="O2" value="7.2" spread="8.1"/>
                    <measurement group_id="O3" value="10.1" spread="9.4"/>
                    <measurement group_id="O4" value="10.5" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Days of Abstinence From Drinking and Number of Days of Clinically Significant Drinking (Measured by Timeline Follow Back at Week 14 and the 6-month Evaluation)</title>
        <time_frame>4+13 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Naltrexone-treated Subjects Will Demonstrate a Significantly Greater Reduction in Cocaine Use Measured by the Number of BE-negative Urine Samples and Significantly Reduced Alcohol Use Measured by Fewer Days of Clinically Significant Drinking.</title>
        <time_frame>4+13 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modafinil-treated Subjects Will Demonstrate a Significantly Greater Reduction in Cocaine Use Measured by the Number of BE-negative Urine Samples and Significantly Reduced Alcohol Use Measured by Fewer Days of Clinically Significant Drinking.</title>
        <time_frame>4+13 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Naltrexone/Modafinil-treated Subjects Will Have Fewer Days of Cocaine Use, More Abstinent Days From Alcohol, and Fewer Heavy Drinking Days During the Follow up Period Compared to Placebo-treated Subjects.</title>
        <time_frame>4+13 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>ModNal</title>
          <description>Nal + Mod
Naltrexone: 150 mg daily for males; 100 mg daily for females
Modafinil: 400 mg daily</description>
        </group>
        <group group_id="E2">
          <title>Naltrexone and Placebo</title>
          <description>Nal
Naltrexone: 150 mg daily for males; 100 mg daily for females</description>
        </group>
        <group group_id="E3">
          <title>Modafinil and Placebo</title>
          <description>Mod
Modafinil: 400 mg daily</description>
        </group>
        <group group_id="E4">
          <title>Double Placebo</title>
          <description>Placebo
Placebo: 400 mg and/or 100-150 mg placebo pills</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="45"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E4" events="11" subjects_affected="7" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Exacerbation of cocaine and alcohol</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression or Hallucinations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Arrested for Homicide</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Kyle Kampman</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>215-222-3200 ext 109</phone>
      <email>kampman@mail.med.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

